

Journal of Visualized Experiments

Improving small RNA-seq: less bias and better detection of 2'-O-methyl RNAs --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE60056R2
Full Title:	Improving small RNA-seq: less bias and better detection of 2'-O-methyl RNAs
Keywords:	small RNA, small RNA-seq, bias, library preparation, next-generation sequencing, NGS, 2'-O-methyl (2'-OMe) RNA, plant microRNA, plant miRNA
Corresponding Author:	Erwin van Dijk I2BC Gif sur Yvette, AB FRANCE
Corresponding Author's Institution:	I2BC
Corresponding Author E-Mail:	Erwin.VANDIJK@i2bc.paris-saclay.fr
Order of Authors:	Erwin van Dijk Evangelia Eleftheriou Claude Thermes
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Gif sur Yvette, France

TITLE:

Improving Small RNA-seq: Less Bias and Better Detection of 2'-O-Methyl RNAs

AUTHORS AND AFFILIATIONS:

Erwin L. van Dijk, Evangelia Eleftheriou and Claude Thermes

Institute for Integrative Biology of the Cell, UMR9198, CNRS CEA Univ Paris-Sud, Université Paris-Saclay, Gif sur Yvette Cedex, France

Corresponding Author:

Erwin L. van Dijk

erwin.vandijk@i2bc.paris-saclay.fr

Email Addresses of Co-authors:

Evangelia Eleftheriou (evangelia.eleftheriou@i2bc.paris-saclay.fr)

Claude Thermes (claudethermes@i2bc.paris-saclay.fr)

KEYWORDS:

small RNA, small RNA-seq, bias, library preparation, next-generation sequencing, NGS, 2'-O-methyl (2'-OMe) RNA, plant microRNA, plant miRNA

SUMMARY:

We present a detailed small RNA library preparation protocol with less bias than standard methods and an increased sensitivity for 2'-O-methyl RNAs. This protocol can be followed using homemade reagents to save cost or using kits for convenience.

ABSTRACT:

The study of small RNAs (sRNAs) by next-generation sequencing (NGS) is challenged by bias issues during library preparation. Several types of sRNA such as plant microRNAs (miRNAs) carry a 2'-O-methyl (2'-OMe) modification at their 3' terminal nucleotide. This modification adds another difficulty as it inhibits 3' adapter ligation. We previously demonstrated that modified versions of the 'TruSeq (TS)' protocol have less bias and an improved detection of 2'-OMe RNAs. Here we describe in detail protocol 'TS5', which showed the best overall performance. TS5 can be followed either using homemade reagents or reagents from the TS kit, with equal performance.

INTRODUCTION:

Small RNAs (sRNAs) are involved in the control of a diversity of biological processes¹. Eukaryotic regulatory sRNAs are typically between 20 and 30 nt in size; the three major types are microRNAs (miRNA), piwi-interacting RNAs (piRNA) and small interfering RNAs (siRNA). Aberrant miRNA expression levels have been implicated in a variety of diseases². This underscores the importance of miRNAs in health and disease and the requirement for accurate, quantitative research tools to detect sRNAs in general.

Next-generation sequencing (NGS) is a widely used method to study sRNAs. Main advantages of NGS as compared with other approaches, such as quantitative PCR or microarray techniques

(qPCR), are that it does not need a priori knowledge of the sRNA sequences and can therefore be used to discover novel RNAs, and in addition it suffers less of background signal and saturation effects. Further, it can detect single nucleotide differences and has a higher throughput than microarrays. However, NGS also has some drawbacks; the cost of a sequencing run remains relatively high and the multistep process required to convert a sample into a library for sequencing may introduce biases. In a typical sRNA library preparation process, a 3' adapter is first ligated to the sRNA (often gel-purified from total RNA) using a truncated version of RNA ligase 2 (RNL2) and a preadenylated 3' adapter (**Figure 1**) in the absence of ATP. This increases the efficiency of sRNA-adapter ligation and reduces the formation of side reactions such as sRNA circularization or concatemerization. Subsequently, a 5' adapter is ligated by RNA ligase 1 (RNL1), followed by reverse transcription (RT) and PCR amplification. All these steps may introduce bias^{3,4}. Consequently, read numbers may not reflect actual sRNA expression levels leading to artificial, method-dependent expression patterns. Specific sRNAs may be either over- or underrepresented in a library, and strongly underrepresented sRNAs may escape detection. The situation is particularly complicated with plant miRNAs, siRNAs in insects and plants, and piRNAs in insects, nematodes and mammals, in which the 3' terminal nucleotide has a 2'-O-methyl (2'-OMe) modification¹. This modification strongly inhibits 3' adapter ligation⁵, making library preparation for these types of RNA a difficult task.

Previous work demonstrated that adapter ligation introduces serious bias, due to RNA sequence/structure effects⁶⁻¹¹. Steps downstream of adapter ligation such as reverse transcription and PCR do not significantly contribute to bias^{6,11,12}. Ligation bias is likely due to the fact that adapter molecules with a given sequence will interact with sRNA molecules in the reaction mixture to form co-folds, that may either lead to favorable or unfavorable configurations for ligation (**Figure 2**). Data from Sorefan et al⁷ suggest that RNL1 prefers a single stranded context, while RNL2 prefers a double strand for ligation. The fact that the adapter/sRNA co-fold structures are determined by the specific adapter and sRNA sequences explains why specific sRNA are over- or underrepresented with a given adapter set. It is also important to note that within a series of sRNA libraries to be compared, the same adapter sequences should be used. Indeed, it has previously been observed that changing adapters by the introduction of different barcode sequences alters miRNA profiles in sequencing libraries^{9,13}.

Randomization of adapter sequences near the ligation junction likely reduces these biases. Sorefan and colleagues⁷ used adapters with 4 random nucleotides at their extremities, designated "High Definition" (HD) adapters, and showed that the use of these adapters lead to libraries that better reflect true sRNA expression levels. More recent work confirmed these observations and revealed that the randomized region does not need to be adjacent to the ligation junction¹¹. This novel type of adapters was named "MidRand" adapters. Together, these results demonstrate that improved adapter design can reduce bias.

Instead of modifying the adapters, bias can be suppressed through the optimisation of reaction conditions. Polyethylene glycol (PEG), a macromolecular crowding agent known to increase ligation efficiency¹⁴, has been shown to significantly reduce bias^{15,16}. Based on these results, several "low bias" kits appeared on the market. These include kits that use PEG in the ligation

reactions, either in combination with classical adapters or HD adapters. Other kits avoid ligation altogether, and use 3' polyadenylation and template switching for 3' and 5' adapter addition, respectively¹². In yet another strategy, 3' adapter ligation is followed by a circularization step, thus omitting 5' adapter ligation¹⁷.

In a previous study, we searched for a sRNA library preparation protocol with the lowest possible levels of bias and the best detection of 2'-OMe RNAs¹². We tested some of the above-mentioned 'low bias' kits, which had a better detection of 2'-OMe RNAs than the standard protocol (TS). Surprisingly however, upon modification (the use of randomized adapters, PEG in the ligation reactions and removal of excess 3' adapter by purification) the latter outperformed the other protocols for the detection of 2'-OMe RNAs. Here, we describe in detail a protocol based on the TS protocol, 'TS5', which had the best overall detection of 2'-OMe RNAs. The protocol can be followed using reagents from the TS kit and one reagent from the 'Nf' kit or, to save money, using homemade reagents, with equal performance. We also provide a detailed protocol for the purification of sRNA from total RNA and the preparation of preadenylated 3' adapter.

PROTOCOL:

1. Isolation of small RNAs

1.1. Extract total RNA using phenol-based reagents or any other method. Verify if the RNA is of good quality.

1.2. Pre-run a 15% TBE-urea gel (see **Table of Materials**) for 15 min at 200 V.

1.3. While the gel is pre-running, mix 5-20 µg of total RNA in a 5-15 µL volume with an equal volume of formamide loading dye (see **Table of Materials**; 95% deionized formamide, 0.025% bromophenol blue, 0.025% xylene cyanol, 5 mM EDTA pH 8) in a 200 µL PCR tube. Likewise, mix 10 µL (200 ng) of small-RNA ladder (see **Table of Materials**) with an equal volume of formamide loading dye. Incubate for 5 min at 65 °C in a thermocycler with heated lid, then place the tubes immediately on ice.

1.4. Load the ladder and the sample on the same gel with at least one lane between them and run at 200 V until the bromophenol has migrated about two-third of the gel length (approximately 40 min).

1.5. Prepare a system to elute the RNA from gel as follows: puncture the bottom of a nuclease-free 0.5 mL micro centrifuge tube with a 21-gauge needle. Place the punctured 0.5 mL tube in a nuclease-free round-bottom 2 mL micro centrifuge tube.

1.6. Remove the gel, and incubate at room temperature with nucleic acid gel stain (see **Table of Materials**) in water for 10-15 min.

1.7. View the gel on a 'Dark Reader' trans illuminator (it is strongly recommended to avoid UV

as this might damage the RNA) and cut out the sample RNA between the 17 nt and the 29 nt ladder bands. Transfer the gel piece to the 0.5 mL tube from step 1.5.

1.8. Centrifuge the 0.5 mL tube in the 2 mL tube in a micro centrifuge at maximum speed for 2 min. Remove the 0.5 mL tube, which should be empty now.

1.9. Add 300 μ L of nuclease-free 0.3 M NaCl to the 2 mL tube containing the crushed gel and rotate for at least 2 h at room temperature or at 4 °C overnight (16 h).

1.10. Transfer the suspension of crushed gel pieces to a spin column (see **Table of Materials**) and centrifuge for 2 min at maximum speed in a micro centrifuge.

1.11. Add 1 μ L (20 μ g/ μ L) of glycogen (see **Table of Materials**) and 950 μ L of room temperature 100% ethanol. Incubate for at least 30 min at -80 °C.

1.12. Centrifuge for 20 min at maximum speed in a micro centrifuge at 4 °C. Remove the supernatant, wash the pellet with 800 μ L of cold 80 % ethanol. Centrifuge again for 5 min, and carefully remove all supernatant. Resuspend RNA pellet in 15 μ L of nuclease free water. Typically, ~5-20 ng of small RNA should be recovered, depending on the amount of input total RNA (~1 ng of small RNA per 1 μ g of input total RNA).

1.13. **Optional step:** Check the quantity and quality of the recovered sRNA (e.g., by capillary gel electrophoresis using a small RNA kit; see **Table of Materials**).

2. Preparation of preadenylated 3' HD adapter

NOTE: Preadenylation of 3' HD adapter was done in a manner similar to the protocol described by Chen et al¹⁸. Note that preadenylated adapter can be ordered directly (/5rApp/ modification), but this is quite expensive.

2.1. Order 5' phosphorylated, 3' blocked 3' HD adapter oligonucleotide. See **Table 1** for sequence and modifications. Note that '3AmMO' is a 3' amino modifier group, most suppliers can produce oligonucleotide with this modification. Dilute in nuclease free water to 100 μ M.

2.2. Set up a 100 μ L reaction containing the following reagents: 10 μ L of oligo (100 μ M), 10 μ L of T4 RNA ligase buffer (10x), 10 μ L of ATP (10 mM), 40 μ L of 50% PEG8000, 5 μ L of T4 RNA ligase 1 (50 units), 25 μ L of nuclease-free water. Incubate overnight at 20 °C.

2.3. Perform a classical phenol-chloroform extraction of the preadenylated oligonucleotide followed by ethanol precipitation. Add 100 μ L of acid (pH 4.5) phenol:chloroform and vortex. Spin for 5 min at maximum speed. Carefully transfer 90 μ L of the upper phase to a new tube; add 10 μ L of 3 M sodium acetate pH 5.2, 1 μ L of ultra-pure glycogen and 250 μ L of cold 100% ethanol.

2.4. Keep at -20 °C for at least 30 min. Centrifuge for 30 min at 4 °C maximum speed. Remove

the supernatant, wash the pellet once with cold 80% ethanol. As an alternative to phenol-chloroform extraction and ethanol precipitation, a nucleotide removal kit can be used (see **Table of Materials**). Resuspend in 10 μ L of water or 10 mM Tris pH 8.

2.5. Verify the efficacy of preadenylation by migrating a small amount on a 15% TBE-urea gel (**Table of Materials**) along with untreated oligonucleotide. The preadenylated adapter should migrate slightly slower than untreated oligonucleotide. It is recommended to gel purify the preadenylated adapter; proceed as described for the isolation of sRNA (steps 1.2-1.12).

3. Library preparation – Protocol TS5

NOTE: We present here the modified TS protocol 'TS5' that we described previously¹² and that can be performed either with reagents from the kit or with self-provided reagents. It should be noted that we obtained similar or even slightly better results with a different protocol, 'TS7'. However, with TS7 it is more difficult to eliminate adapter dimers. We have therefore preferred to describe TS5 in detail, but TS7 can be followed by simply replacing the adapters. For TS7 use the 'MidRand-Like (MRL)' adapter sequences (**Table 1**). Note that here the randomized regions are in the middle of the adapters. Primers for reverse transcription and PCR will hybridize to the sequences downstream of the randomized region in the 3' adapter and upstream of the randomized region in the 5' adapter. Sequencing will start from the first randomized nucleotide in the 5' adapter.

3.1. 3' adapter ligation.

3.1.1. Combine 1 μ L of preadenylated 3' HD adapter (10 μ M) with 1 μ L of purified small RNA (~0.1-1 μ M) in a 0.2 mL micro centrifuge tube. Incubate for 2 min at 72 °C in a thermo cycler, then put directly on ice.

3.1.2. Add 4 μ L of 50 % PEG 8000 (viscous solution; pipet slowly), 1 μ L of RNA ligase buffer (10x), 1 μ L of H₂O, 1 μ L of T4 RNA ligase2 truncated, and 1 μ L of RNase inhibitor. Incubate overnight at 16 °C.

3.2. Elimination of unligated 3' adapter

3.2.1. Add 10 μ L of nuclease-free water and mix well. Add 6 μ L of 3 M NaOAc pH 5.2 or 'Adapter Depletion Solution' from the Nf kit (**Table of Materials**) and mix well. Add 40 μ L of magnetic purification beads (**Table of Materials**) and 60 μ L of isopropanol and mix well. Incubate for 5 min at room temperature.

3.2.2. Put the sample in a magnetic rack until the solution appears clear. Remove and discard the supernatant.

3.2.3. Add 180 μ L of freshly prepared 80 % ethanol. Incubate for ~30 s, then remove. Take care to use freshly prepared 80% ethanol and do not incubate with 80% ethanol for extended periods.

3.2.4. Briefly spin the tube and remove residual liquid that may have collected at the bottom of the well. Let the beads dry for 2 min, then resuspend in 22 μ L of 10 mM Tris pH 8 or resuspension buffer from the Nf kit. Incubate for 2 min, then magnetize the sample until the solution appears clear.

3.2.5. Add 6 μ L of 3 M NaOAc pH 5.2 to a new tube. Transfer 20 μ L of the supernatant from the previous step to this new tube and mix by pipetting. Add 40 μ L of magnetic beads and 60 μ L of 100% isopropanol and mix well by pipetting. Incubate for 5 min.

3.2.6. Magnetize the sample until the solution appears clear, then remove and discard the supernatant.

3.2.7. Add 180 μ L of freshly prepared 80 % ethanol. Incubate for ~30 s, then remove. Take care to use freshly prepared 80% ethanol and do not incubate for with 80% ethanol for extended periods.

3.2.8. Briefly spin the tube and remove residual liquid that may have collected at the bottom of the well. Let the beads dry for 2 min, and resuspend in 10 μ L of nuclease-free water. Incubate for 2 min, then magnetize the sample until the solution appears clear.

3.2.9. Transfer 9 μ L of supernatant to a new tube. Add 1 μ L of T4 RNA ligase buffer (10x) and 1 μ L of water or 2 μ L of ligase buffer from the TS kit.

3.3. Ligation of 5' adapter.

3.3.1. Add 1 μ L of 5' HD adapter (10 μ M; **Table 1**) to a 200 μ L PCR tube in a thermo cycler with heated lid. Incubate for 2 min at 70 $^{\circ}$ C, then put the tube directly on ice.

3.3.2. Add 1 μ L of 10 mM ATP and 1 μ L of T4 RNA ligase 1. Mix well by gently pipetting. Add 3 μ L of this mix to the 3' ligated RNA from step 3.2.9 and mix by pipetting. Incubate for 1 h at 28 $^{\circ}$ C.

3.4. Reverse transcription (RT)

3.4.1. Transfer 6 μ L of 3' and 5' adapter ligated RNA to a new 200 μ L PCR tube (keep the remaining ~8 μ L at -80 $^{\circ}$ C for later use if necessary). Add 1 μ L of RT primer (10 μ M) and mix by pipetting. Incubate for 2 min at 70 $^{\circ}$ C, then put the tube directly on ice.

3.4.2. Add the following reagents for RT: 2 μ L of 5x first strand buffer, 0.5 μ L of 12.5 mM dNTP mix, 1 μ L of 100 mM DTT, 1 μ L of RNase inhibitor, and 1 μ L of reverse transcriptase (**Table of Materials**). Incubate for 1 h at 50 $^{\circ}$ C.

3.5. PCR amplification

3.5.1. Add the following reagents to the 12.5 μ L of RT reaction mixture: 10 μ L of PCR polymerase buffer, 2 μ L of universal P5 primer (10 μ M), 2 μ L of P7-index primer (10 μ M), 1 μ L of 12.5 mM dNTPs, 0.5 μ L of DNA polymerase, and 22 μ L of water. Keep the reaction on ice until use.

3.5.2. Run the following PCR program: 98 $^{\circ}$ C for 30 s, 11 cycles (98 $^{\circ}$ C for 10 s, 60 $^{\circ}$ C for 30 s and 72 $^{\circ}$ C for 15 s) and 72 $^{\circ}$ C for 10 min. Keep the reaction at 4 $^{\circ}$ C when finished.

NOTE: Concerning the number of PCR cycles: we typically perform 11 cycles, but this should be optimized by the user. Try to perform the smallest possible number of PCR cycles.

3.6. Gel purification

3.6.1. Run 5, 10 and 20 μ L of PCR product on a native 6% TBE gel (see **Table of Materials**) along with a suitable ladder (see **Table of Materials**). Run the gel for about 1 h (until the bromophenol blue reaches the bottom; this dye migrates at the 65 bp position).

3.6.2. Remove the gel, and incubate with nucleic acid gel stain (see **Table of Materials**) in water for 10-15 min.

3.6.3. View the gel on a "Dark Reader" trans illuminator (it is strongly recommended to avoid UV as this might damage the RNA) and cut out the library band at 150 bp. Prepare a system to elute the RNA from gel as described in step 1.5 and transfer the gel piece to the 0.5 mL tube.

3.6.4. Centrifuge in a micro centrifuge at maximum speed for 2 min. Remove the 0.5 mL tube, which should be empty now.

3.6.5. Add 300 μ L of nuclease-free water to the 2 mL tube containing the crushed gel and rotate for at least 2 h at room temperature or at 4 $^{\circ}$ C overnight.

3.6.6. Transfer the suspension of crushed gel pieces in water to a spin column and centrifuge for 2 min at maximum speed.

3.6.7. Add 1 μ L of (20 μ g/ μ L) glycogen, 30 μ L of 3 M NaOAc and 975 μ L of ice cold 100% ethanol. Centrifuge for 20 min at max speed at 4 $^{\circ}$ C.

3.6.8. Resuspend the pellet in 20 μ L of 10 mM Tris pH8. Use 1 μ L for concentration measurement and 1 μ L for quality control.

4. Data analysis

NOTE: The data analysis procedure described below is based on the Linux operating system Ubuntu 16.04 LTS.

4.1. Treatment of raw sequence files

4.1.1. Download the FASTQ sequence file(s) generated during the sequencing run. If required, perform demultiplexing with **bcl2fastq2** (version V2.2.18.12; a manual can be downloaded from the following link: http://emea.support.illumina.com/sequencing/sequencing_software/bcl2fastq-conversion-software/documentation.html).

Use the following command:

```
nohup Pathway_of_bcl2fastq/bcl2fastq --runfolder-dir Pathway_of_Run --ignore-missing-bcl --output-dir Pathway_of_Output_Directory --barcode-mismatches 1 --aggregated-tiles AUTO -r 16 -d 16 -p 16 -w 16
```

4.1.2. Remove adapter sequences using Cutadapt¹⁹ version 1.15. A manual can be downloaded here: <https://cutadapt.readthedocs.io/en/stable/guide.html>.

Use the following command:

```
Pathway_to_cutadapt/cutadapt -a TGGGAATTCTCGGGTGCCAAGG -n 5 -O 4 -m 10 -j 0 --nextseq-trim 10 -o Output_File_Read1_cutadapt.fastq.gz Input_File_Read1.fastq.gz
```

Note that the sequence in the command corresponds to the 3' HD adapter **without** the 4 random nucleotides; these will therefore not be removed during this step.

4.1.3. Use seqtk (<https://github.com/lh3/seqtk>) for the removal of the terminal random nucleotides in the sequencing reads. Use the following command (variable names in bold):

```
seqtk trimfq -b 4 -e 4 Output_File_Read1_cutadapt.fastq > Output_File_Read1_trimmed.fastq
```

4.1.4. Use the following awk command in order to discard the sequences shorter than 10 nt:

```
awk 'BEGIN {FS = "\t" ; OFS = "\n"} {header = $0 ; getline seq ; getline qheader ; getline qseq ; if (length(seq) >= 10) {print header, seq, qheader, qseq}}' Output_File_Read1_trimmed.fastq > Length_Filtered.fastq
```

4.2. Mapping of the trimmed sequences

4.2.1. Download the database corresponding to the organism of study from miRBase as follows. Go to <http://www.mirbase.org/ftp.shtml> and download the 'mature.fa' file. Note that the sequences are indicated in RNA notation. Replace the U residues by T with the following command:

```
sed -i '/^>/! s/U/T/g' mature.fa
```

NOTE: This will yield a complete list of all miRNAs in miRBase, originating from a variety of organisms.

4.2.2. Select the miRNA sequences of your organism of interest with the following command:

```
awk '/name_of_the_organism/{print; nr[NR+1]; next}; NR in nr' mature.fa >
mature_name_of_the_organism_mirs.fa
```

4.2.3. Map the reads to the above-created file using Bowtie2²⁰ (version 2.3.0) allowing no mismatches. First, build an index for your file with the following command:

```
bowtie2-build mature_name_of_the_organism_mirs.fa mature_name_of_the_organism_mirs
```

4.2.4. Align the sequencing reads to the database, requiring that a read maps entirely to a miRNA of the database, without any mismatches. To this end, use the following tool:

```
bowtie2 -N 0 -L 10 --score-min C,0,0 --end-to-end --time -x
mature_name_of_the_organism_mirs -U Length_Filtered.fastq -S
Length_Filtered_ALIGNMENT.sam
```

NOTE: The option: `--score-min C,0,0` ensures that alignment is without any mismatches. For an explanation of the various parameters in the tool, please visit the following website: <http://bowtie-bio.sourceforge.net/bowtie2/manual.shtml>

4.2.5. To discard the reads that did not align, use the following command:

```
samtools view -F 4 Length_Filtered_ALIGNMENT.sam > Reads_aligned_to_Mirs.sam
```

NOTE: As a result of these steps, you should now have obtained the aligned reads, corresponding to miRNAs.

REPRESENTATIVE RESULTS:

Critical steps are the isolation of the small RNA fraction of the starting total RNA material (**Figure 3**) and the desired final library product (**Figure 4**). Both steps involve polyacrylamide gel purification; small RNA is isolated from 15% TBE urea gels, while the final libraries are isolated from 6% native TBE gels. Small RNA isolated from gel can be analyzed on a small RNA capillary electrophoresis chip (**Table of Materials; Figure 3B**). This will allow users to estimate the amount of small RNA recovered and the proportion of miRNA in the preparation.

Gel purification of the final library product is a delicate step as a number of additional products are formed that migrate close to the desired library. It is important to not overload the gel as this will increase the risk to contaminate the library with other species such as adapter dimers. As an example (**Figure 4**), increasing amounts of PCR-amplified library (from *B. napus* RNA) were loaded on the gel and the product corresponding to the expected size (150 bp) was cut out (**Figure 4A**). After elution, the purified library was checked on a capillary gel electrophoresis chip; in addition to the expected 150 bp product, an increasing proportion of a 130 bp species, corresponding to adapter dimers was observed as increasing amounts of PCR product were loaded (**Figure 4B,C**).

We have tested if protocol TS5 performs similarly with homemade reagents as with reagent from the kits. To this end, we prepared libraries from a mix of synthetic small RNAs 1-6, each present without or with a 2'-OMe modification, as done in our previous study¹². **Figure 5** shows the

proportion of reads corresponding to each of these RNAs obtained previously and with the new libraries made using reagents from the TS and Nf kits or from other suppliers. As can be seen, very similar results were obtained.

Figure 6 shows a comparison of the performance of protocol TS5 with the standard TS protocol for the detection of plant (*A. thaliana* and *B. napus*) miRNAs, which are 2'-OMe modified, and of unmodified human miRNAs. We also tested the detection of piRNAs, 2'-OMe modified in human samples. As can be seen, TS5 performs significantly better than TS for the detection of 2'-OMe RNAs but not for unmodified RNAs. However, also for unmodified sRNAs, even though not a larger number of RNAs are detected, the obtained read numbers probably better reflect true expression levels with TS5 than with TS due to lower levels of bias.

FIGURE AND TABLE LEGENDS:

Figure 1. Schematic representation of the sRNA library preparation workflow for Illumina sequencing. First, sRNAs are isolated by a gel purification step. Here, the size range of miRNAs is indicated but any other size range could be selected, depending on the RNAs of interest. A quality control (QC) step is then performed to check the quality and quantity of isolated sRNA. During library preparation, a preadenylated (App) 3' adapter is first ligated to the sRNA. Then, a 5' adapter is ligated. Subsequently reverse transcription is performed using a primer complementary to the 3' adapter, followed by PCR amplification, during which the Illumina P5, P7, and index ('In') sequences are added. The resulting library is gel purified, followed by a quality control step. Then the library is sequenced, and data are analyzed.

Figure 2. Bias due to sequence-dependent adapter-sRNA co-folding. In the adapter ligation mixture, adapters will cofold with sRNAs in a manner that depends on the sequence of the adapter and the sRNA. Thus, different sRNAs (illustrated by examples a, b, and c; indicated by different shades of green) will cofold differently with a given adapter (the 3' adapter is indicated in red, the 5' adapter is indicated in blue). The black arrows indicate ligation junctions. This may lead to a favorable or unfavorable context for ligation. As RNL2 appears to prefer a double stranded environment, 3' ligation is expected to be more efficient for RNAs a and b than for RNA c. With RNL1 having a preference for a single stranded region around the ligation junction, 5' adapter ligation may be most efficient for RNA a, followed by b and least efficient for c. Together this may result in an overrepresentation of sRNA a, an intermediate representation of RNA b and an underrepresentation of RNA c in the final library, even if the three RNAs are present at equal amounts in the original RNA sample. Note that in a similar fashion, a given sRNA will be represented differently when changing the adapter sequence (e.g., by adding different barcodes).

Figure 3. Isolation of small RNA and quality control. (A). Electrophoretic separation of *Brassica napus* total RNA (10 µg) on a 15% TBE urea denaturing polyacrylamide gel. A small RNA ladder (see **Table of Materials**) was migrated along as a molecular size marker. After migration the gel was stained and the RNA was visualized on a trans illuminator. The region from 17 to 29 nucleotides was cut out (indicated by a red rectangle) and RNA was eluted. **(B).** The quality of the purified RNA was checked by capillary gel electrophoresis. Note that this analysis provides

information on the proportion of miRNA in the sample (93% in this case).

Figure 4. Gel purification of a *B. napus* small RNA library prepared following protocol TS5 and quality control. (A). Increasing amounts of a PCR amplified library from *B. napus* small RNA were loaded on a 6% native TBE gel; 2.5 μ L (a), 5 μ L (b), 10 μ L (c) or 20 μ L (d) PCR product. A 50 bp ladder was migrated alongside. PCR products migrating at the expected 150 pb position were isolated (red rectangle), DNA was eluted and purified. **(B).** Quality control of the purified library; gel representation. **(C).** Electropherogram representation of the same analysis. As can be seen, the 150 pb product is increasingly contaminated with adapter dimers (~130 bp) as larger amounts of PCR product are migrated on gel.

Figure 5. Protocol TS5 performs similarly with reagents from the TS and Nf kits or with reagents from other suppliers. Histograms representing the percentage of the total numbers of raw reads (before trimming) corresponding to RNA(OMe)1-6 with protocol TS5 followed with reagents from the TS and Nf kits (blue bars), or reagents from other suppliers (orange bars). For comparison, results from our previous study are shown by grey bars. The total numbers of reads corresponding to RNA1-6 (*total RNA*) or RNA-OMe1-6 (*total RNA-OMe*) are shown as well. Shown are the mean values of at least two independent experiments. Error bars represent standard deviations. Part of this figure has been modified from Dard-Dascot et al, 2018¹²

Figure 6. Comparison of miRNA detection of protocol TS5 with the classical TS method. (A). The proportion of reads mapping to *A. thaliana*, *B. napus*, or *H. sapiens* miRNAs in miRBase were determined. We also mapped the reads of the human libraries to piRBase for piRNA detection. Note that *A.thaliana* and *B.napus* miRNAs, as well as human piRNAs are 2'-OMe modified, in contrast to human miRNAs. Shown are the mean values of at least two independent experiments and the error bars represent standard deviations. **(B).** Numbers of miRNAs (or piRNAs) identified. We determined the numbers of known miRNAs from the different species identified with protocols TS or TS5. Note that for *A. thaliana*, *B. napus*, or *H. sapiens*, 427, 92, and 2588 miRNAs have been registered in miRBase, respectively. 0.5 million reads from the TS or TS5 libraries were mapped to *B. napus* miRNAs in miRbase, 1 million reads were mapped to the *A. thaliana* or human databases. Shown are the mean values of at least two independent experiments with standard deviations represented by error bars. This figure has been modified from Dard-Dascot et al, 2018¹².

Table 1. Oligonucleotides used with this protocol.

DISCUSSION:

Small RNA library preparation remains challenging due to bias, mainly introduced during adapter ligation steps. RNAs with a 2'-OMe modification at their 3' end such as plant miRNAs, piRNA in insects, nematodes and mammals, and small interfering RNAs (siRNA) in insects and plants are particularly difficult to study because the 2'-OMe modification inhibits 3' adapter ligation. A number of solutions have been proposed in the literature to improve sRNA library preparation protocols, but most commercially available kits are still based on the classical TS protocol, which has severe bias. A few 'low bias' kits exist, however, including the Nf kit with randomized adapters

and PEG in the ligation reactions, and a few kits appeared recently that avoid adapter ligation altogether¹². We reported previously that Nf detects more different miRNAs than the standard TS protocol, but protocol 'S' (without adapter ligation) performed relatively poorly due to a significant formation of side-products¹². Surprisingly, upon modification the TS protocols had a more sensitive detection of 2'-OMe sRNAs than the other protocols, but not of normal sRNAs. We chose here to describe in detail the TS5 protocol, in which the adapters are randomized at their extremities, PEG is used in the ligation reactions and excess 3' adapter is eliminated by purification on beads. It should be noted here that a different protocol (TS7), using MRL adapters may perform slightly better than the TS5 protocol. However, as there are only minor differences between the two and because with TS7, it is more difficult to separate the desired library product from adapter dimers, we preferred here to describe in detail the TS5 protocol. However, users can, if desired, replace the TS5 adapters by TS7 adapters. Note that these are slightly longer leading to a final library product of ~170 bp rather than ~150 bp.

The possibility to perform protocol TS5 or TS7 with 'home-made' materials allows to substantially reduce cost. However, there may be a larger variability in terms of quality with home-made materials; especially home-made pre-adenylated 3' adapter may be subject to variable quality due to varying efficacies of pre-adenylation. It is therefore recommended to prepare a large stock and if a new stock is prepared, compare its performance with the previous one. A control RNA sample can be used for this purpose.

A disadvantage of the protocols describe herein is the relatively strong formation of side-products and the difficulty to separate the desired library from these products. Care must be taken to not overload the acrylamide gel for purification. Recently, modified adapters were developed that have a strongly reduced tendency to form dimers²¹. A 2'-OMe modification at the 3' end of the 5' adapter combined with a methylphosphonate modification at the 5' extremity of the 3' adapter efficiently suppressed adapter dimers. It will be interesting to test such modified adapters in the herein described protocol.

The gel purification steps in protocol TS5 are relatively labor-intensive. If the use of modified adapters efficiently reduces the formation of adapter dimers, gel purification of the final library may not be necessary anymore. In addition, as an alternative to the gel purification step to isolate small RNA (step 1), a strategy using magnetic beads to enrich for small RNAs exists (https://ls.beckmancoulter.co.jp/files/appli_note/Supplemental_Protocol_for_miRNA_.pdf). We have not used this method ourselves, but it is worth testing and if it works well it could significantly simplify the protocol.

In conclusion, while protocol TS5 could be further improved, it performs better than commercially available kits, at least those tested in our previous comparative analysis, for the detection of 2'-OMe sRNA. It can be followed using home-made materials, allowing significant cost reduction. For convenience, and perhaps more constant performance, reagents from the TS and Nf kits can be used.

ACKNOWLEDGEMENTS:

This work was supported by the National Center for Scientific Research (CNRS), The French Alternative Energies and Atomic Energy Commission (CEA) and Paris-Sud University. All library preparation, Illumina sequencing and bioinformatics analyses for this study were performed at the I2BC Next-Generation Sequencing (NGS) facility. The members of the I2BC NGS facility are acknowledged for critical reading of the manuscript and helpful suggestions.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Ghildiyal, M. & Zamore, P. D. Small silencing RNAs: an expanding universe. *Nature Reviews Genetics* **10**, 94-108, doi:nrg2504 [pii];10.1038/nrg2504 [doi] (2009).
- 2 Chang, T. C. & Mendell, J. T. microRNAs in vertebrate physiology and human disease. *Annual Review of Genomics and Human Genetics* **8**, 215-239, doi:10.1146/annurev.genom.8.080706.092351 [doi] (2007).
- 3 Zhuang, F., Fuchs, R. T., & Robb, G. B. Small RNA expression profiling by high-throughput sequencing: implications of enzymatic manipulation. *Journal of Nucleic Acids* **2012**, 360358, doi:10.1155/2012/360358 [doi] (2012).
- 4 van Dijk, E. L., Jaszczyszyn, Y., & Thermes, C. Library preparation methods for next-generation sequencing: tone down the bias. *Experimental Cell Research* **322**, 12-20, doi:S0014-4827(14)00016-0 [pii];10.1016/j.yexcr.2014.01.008 [doi] (2014).
- 5 Munafo, D. B. & Robb, G. B. Optimization of enzymatic reaction conditions for generating representative pools of cDNA from small RNA. *RNA* **16**, 2537-2552, doi:rna.2242610 [pii];10.1261/rna.2242610 [doi] (2010).
- 6 Hafner, M. *et al.* RNA-ligase-dependent biases in miRNA representation in deep-sequenced small RNA cDNA libraries. *RNA* **17**, 1697-1712, doi:rna.2799511 [pii];10.1261/rna.2799511 [doi] (2011).
- 7 Sorefan, K. *et al.* Reducing ligation bias of small RNAs in libraries for next generation sequencing. *Silence* **3**, 4, doi:1758-907X-3-4 [pii];10.1186/1758-907X-3-4 [doi] (2012).
- 8 Sun, G. *et al.* A bias-reducing strategy in profiling small RNAs using Solexa. *RNA* **17**, 2256-2262, doi:rna.028621.111 [pii];10.1261/rna.028621.111 [doi] (2011).
- 9 Jayaprakash, A. D., Jabado, O., Brown, B. D., & Sachidanandam, R. Identification and remediation of biases in the activity of RNA ligases in small-RNA deep sequencing. *Nucleic Acids Research* **39**, e141, doi:gkr693 [pii];10.1093/nar/gkr693 [doi] (2011).
- 10 Zhuang, F., Fuchs, R. T., Sun, Z., Zheng, Y. & Robb, G. B. Structural bias in T4 RNA ligase-mediated 3'-adapter ligation. *Nucleic Acids Research* **40**, e54, doi:gkr1263 [pii];10.1093/nar/gkr1263 [doi] (2012).
- 11 Fuchs, R. T., Sun, Z., Zhuang, F. & Robb, G. B. Bias in ligation-based small RNA sequencing library construction is determined by adaptor and RNA structure. *PLoS. One* **10**, e0126049, doi:10.1371/journal.pone.0126049 [doi];PONE-D-14-58561 [pii] (2015).
- 12 Dard-Dascot, C. *et al.* Systematic comparison of small RNA library preparation protocols for next-generation sequencing. *BMC Genomics* **19**, 118, doi:10.1186/s12864-018-4491-6 (2018).
- 13 Van Nieuwerburgh, F. *et al.* Quantitative bias in Illumina TruSeq and a novel post

amplification barcoding strategy for multiplexed DNA and small RNA deep sequencing. *PLoS One* **6**, e26969, doi:10.1371/journal.pone.0026969 (2011).

14 Harrison, B. & Zimmerman, S. B. Polymer-stimulated ligation: enhanced ligation of oligo- and polynucleotides by T4 RNA ligase in polymer solutions. *Nucleic Acids Research* **12**, 8235-8251 (1984).

15 Song, Y., Liu, K. J. & Wang, T. H. Elimination of ligation dependent artifacts in T4 RNA ligase to achieve high efficiency and low bias microRNA capture. *PLoS. One* **9**, e94619, doi:10.1371/journal.pone.0094619 [doi];PONE-D-13-50237 [pii] (2014).

16 Zhang, Z., Lee, J. E., Riemondy, K., Anderson, E. M. & Yi, R. High-efficiency RNA cloning enables accurate quantification of miRNA expression by deep sequencing. *Genome Biology* **14**, R109, doi:gb-2013-14-10-r109 [pii];10.1186/gb-2013-14-10-r109 [doi] (2013).

17 Barberan-Soler, S. *et al.* Decreasing miRNA sequencing bias using a single adapter and circularization approach. *Genome Biology* **19**, 105, doi:10.1186/s13059-018-1488-z (2018).

18 Chen, Y. R. *et al.* A cost-effective method for Illumina small RNA-Seq library preparation using T4 RNA ligase 1 adenylated adapters. *Plant Methods* **8**, 41, doi:1746-4811-8-41 [pii];10.1186/1746-4811-8-41 [doi] (2012).

19 M., M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet*, doi:http://dx.doi.org/10.14806/ej.17.1.200 (1905).

20 Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biology* **10**, R25, doi:gb-2009-10-3-r25 [pii];10.1186/gb-2009-10-3-r25 [doi] (2009).

21 Shore, S. *et al.* Small RNA Library Preparation Method for Next-Generation Sequencing Using Chemical Modifications to Prevent Adapter Dimer Formation. *PLoS. One* **11**, e0167009, doi:10.1371/journal.pone.0167009 [doi];PONE-D-16-33596 [pii] (2016).




Figure 1.




Figure 2




Figure 3.




Figure 4.




Figure 5.




Figure 6.

Table 1. Oligonucleotides required for this protocol				
Name oligonucleotide	5' modification	3' modification	sequence 5' to 3'	purification
5' HD (TS5) adapter	5AmMC6		[5AmMC6]GTTTCAGAGTTCTACAGTCCGACGATC	HPLC
3' HD (TS5) adapter	phosphate	3AmMO	[Phos]rNrNrNrNTGGAATTCTCGGGTGCCAAGG[3AaMO] (note that this oligo is a DNA-RNA chimeric; the three 3' terminal nts are RNA)	HPLC
5' MRL (TS7) adapter	5AmMC6		[5AmMC6]GTTTCAGAGTTCTACAGTCCGACGATC	HPLC
3' MRL (TS7) adapter	phosphate	3AmMO	[Phos]GTATCGTNNNNNTGGAATTCTCGG[3AmMO] (note that this oligo is a DNA-RNA chimeric; the seven 3' terminal nts are RNA)	HPLC
RT primer			GCCTTGGCACCCGAGAATTCCA	HPLC
Universal P5 primer			AATGATACGGCGACCA	HPLC
P7-index primer			CAAGCAGAAGACGGCATACGAGATNNNNNGTGACTGGAGTTCCTTGGCACCCGAGAATTCCA (NNNNNN = index)	HPLC
			index 1: CGTGAT	
			index 2: ACATCG	
			index 3: GCCTAA	
			index 4: TGGTCA	
			index 5: CACTGT	
			index 6: ATTGGC	
			index 7: GATCTG	
			index 8: TCAAGT	
			index 9: CTGATC	
			index 10: AAGCTA	
			index 11: GTAGCC	
			index 12: TACAAG	

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
2100 Bioanalyzer Instrument	Agilent	G2939BA	
Acid-Phenol:Chloroform, pH 4.5 (with IAA, 125:24:1)	ThermoFisher	AM9720	
Adenosine 5'-Triphosphate (ATP)	Nex England Biolabs	P0756S	
Agencourt AMPure XP beads	Beckman Coulter	A63880	
Bioanalyzer High Sensitivity DNA Kit	Agilent	5067-4626	
Bioanalyzer Small RNA Kit	Agilent	5067-1548	
Corning Costar Spin-X centrifuge tube filters	Sigma Aldrich	CLS8162-96EA	
Dark Reader transilluminator	various suppliers		
HotStart PCR Kit, with dNTPs	Kapa Biosystems	KK2501	
NEXTflex small RNA-seq V3 kit	BIOO Scientific	NOVA-5132-05	optional
Novex TBE gels 6%	ThermoFisher	EC6265BOX	
Novex TBE Urea gels 15%	ThermoFisher	EC6885BOX	
QIAquick Nucleotide Removal Kit	Qiagen	28304	
Qubit 4 Quantitation Starter Kit	ThermoFisher	Q33227	
RNA Gel Loading Dye (2X)	ThermoFisher	R0641	
RNA Gel Loading Dye (2X)	ThermoFisher	R0641	
RNase Inhibitor, Murine	Nex England Biolabs	M0314S	
SuperScript IV Reverse Transcriptase	ThermoFisher	18090200	
SYBR Gold Nucleic Acid Gel Stain	ThermoFisher	S11494	
T4 RNA Ligase 1 (ssRNA Ligase)	Nex England Biolabs	M0204S	
T4 RNA Ligase 2, truncated	Nex England Biolabs	M0242S	
TrackIt 50 bp DNA ladder	ThermoFisher	10488043	
TruSeq Small RNA Library Prep Kit	Illumina	RS-200-0012/24/36/48	optional
UltraPure Glycogen	ThermoFisher	10814010	
XCell SureLock Mini-Cell	ThermoFisher	E10001	
XCell SureLock Mini-Cell	ThermoFisher	E10001	
ZR small RNA ladder	Zymo Research	R1090	
			the last two numbers correspond to the set of indexes



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Improving small RNA-seq: less bias and better detection of 2'-O-methyl RNAs

Author(s):

Erwin C. von Dylk, Evangelina Eleftheriou, Claude Thénnes

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Erwin van Dijk	
Department:	I2BC	
Institution:	CNRS	
Title:	Dr.	
Signature:		Date: 28/03/2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Rebuttal letter 2.

We are grateful for the editorial comments and we have taken advantage of these to improve our manuscript. Please find below our detailed responses to the comments:

1. We have carefully proofread the manuscript and we have corrected some remaining errors.
2. We acknowledge that the paper still contained a number of company names. We have now carefully removed all of these and we have checked if all materials required to perform the protocol are referenced in the Table of Materials.
3. Paragraph 3, lines 188-197: 'We present here...the 5' adapter.' The text here is not really a note but rather an introduction. We have therefore removed the word 'NOTE' at the beginning.
4. Step 1.6: incubation should be done at room temperature. This has been clarified in the description of the step.
5. We agree that step 2.3 was a bit long. We have therefore subdivided this step in three separate steps 2.3-2.5.
6. We have rewritten the requested sections to make sure original language is used.